Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announced that CEO and Chairman John Yu, MD, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference, scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel in New York, is a key event for the investment community to learn about emerging companies in the biotech sector.
The company's lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. This approach addresses a critical problem in oncology: patients who initially respond to treatment often develop resistance, leading to disease progression.
Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs in oncology. Prostate cancer is the second most common cancer in men worldwide, and lung cancer remains the leading cause of cancer death. The ability to overcome resistance could transform outcomes for these patients.
The presentation at the H.C. Wainwright conference represents an opportunity for the company to showcase its progress and potential to the investment community. For investors, this presentation is important because it provides insight into the company's pipeline and scientific approach. The company's use of structural biology to overcome drug resistance and immune suppression in cancer positions it at the forefront of oncology therapeutics.
Investors and stakeholders can access the latest news and updates relating to KAPA through the company's newsroom at https://ibn.fm/KAPA. The full press release detailing the conference participation is available at https://ibn.fm/mdybH.
The implications of Kairos Pharma's work are significant. If ENV105 proves successful in clinical trials, it could become a cornerstone therapy for patients who have exhausted other options. The company's focus on drug resistance mechanisms represents an important advancement in cancer treatment research, particularly for patients who develop resistance to standard therapies. This announcement matters because it highlights progress in a field where new approaches are urgently needed.
